South Korea
· Delayed Price · Currency is KRW HLB Life Science Statistics
Total Valuation
HLB Life Science has a market cap or net worth of KRW 1.11 trillion. The enterprise value is 1.16 trillion.
| Market Cap | 1.11T |
| Enterprise Value | 1.16T |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB Life Science has 118.65 million shares outstanding. The number of shares has increased by 0.69% in one year.
| Shares Outstanding | 118.65M |
| Shares Change (YoY) | +0.69% |
| Shares Change (QoQ) | -2.32% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 6.87% |
| Float | 97.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.64 |
| PB Ratio | 3.09 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -125.87 |
| EV / Sales | 12.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.84 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.41 |
| Quick Ratio | 1.31 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.15 |
| Interest Coverage | -1.25 |
Financial Efficiency
Return on equity (ROE) is -3.06% and return on invested capital (ROIC) is -4.00%.
| Return on Equity (ROE) | -3.06% |
| Return on Assets (ROA) | -3.85% |
| Return on Capital (ROIC) | -4.00% |
| Revenue Per Employee | 654.01M |
| Profits Per Employee | -64.82M |
| Employee Count | 142 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 16.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.11% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +0.11% |
| 50-Day Moving Average | 10,904.80 |
| 200-Day Moving Average | 12,770.90 |
| Relative Strength Index (RSI) | 28.99 |
| Average Volume (20 Days) | 706,475 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB Life Science had revenue of KRW 92.87 billion and -9.20 billion in losses. Loss per share was -87.19.
| Revenue | 92.87B |
| Gross Profit | -2.95B |
| Operating Income | -27.93B |
| Pretax Income | -7.14B |
| Net Income | -9.20B |
| EBITDA | -21.17B |
| EBIT | -27.93B |
| Loss Per Share | -87.19 |
Balance Sheet
The company has 71.92 billion in cash and 119.55 billion in debt, giving a net cash position of -47.63 billion or -401.48 per share.
| Cash & Cash Equivalents | 71.92B |
| Total Debt | 119.55B |
| Net Cash | -47.63B |
| Net Cash Per Share | -401.48 |
| Equity (Book Value) | 359.37B |
| Book Value Per Share | 3,026.46 |
| Working Capital | 27.69B |
Cash Flow
In the last 12 months, operating cash flow was -28.10 billion and capital expenditures -27.48 billion, giving a free cash flow of -55.58 billion.
| Operating Cash Flow | -28.10B |
| Capital Expenditures | -27.48B |
| Free Cash Flow | -55.58B |
| FCF Per Share | -468.47 |
Margins
Gross margin is -3.17%, with operating and profit margins of -30.07% and -9.91%.
| Gross Margin | -3.17% |
| Operating Margin | -30.07% |
| Pretax Margin | -7.69% |
| Profit Margin | -9.91% |
| EBITDA Margin | -22.79% |
| EBIT Margin | -30.07% |
| FCF Margin | -59.85% |
Dividends & Yields
HLB Life Science does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.69% |
| Shareholder Yield | -0.69% |
| Earnings Yield | -0.93% |
| FCF Yield | -5.01% |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.0516983.
| Last Split Date | Dec 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.0516983 |
Scores
HLB Life Science has an Altman Z-Score of 5.51.
| Altman Z-Score | 5.51 |
| Piotroski F-Score | n/a |